AbbVie Inc. Increases Humira Prices, Receives FDA Approval For New Drug

Image result for AbbVie

Pharmaceutical sector is in a bind as the new Donald Trump administration begins to start functioning. The new president has eluded that the drug companies may see lots of changes coming their way. One big area of concern is the drug pricing. Regardless of the political scenario, AbbVie (ABBV) company has announced its decision to hike the price of its Humira drug by over 8%.

However, AbbVie said that it is unlikely to raise the price of the drug again this year. Thus, the company is leaning away from its long-term practice of increasing the price twice annually. The most recent price hike is milder than its previous bumps. The company had increased the price by 9.9% and 7.9% last year.

Humira is the main revenue generator for AbbVie. However, the main patent for the drug expired last year. The company expects the IP moat to offer protection biosimilar encroachment until 2022. The company stock started out well this year and offered dividend. Its 12 months gain stands at nearly 4%.

Another positive news for the company came out during the weekend as it announced receiving the FDA approval for its lymphoma drug, IMBRUVICA (ibrutinib). The drug candidate had shown 46% efficacy rate in clinical trial. The drug has been approved as a therapy for patients affected with marginal zone lymphoma.

Subscribe to KKD Healthcare Analytics for an entire Biotech digest. 

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Bruce Powers 3 years ago Member's comment

Excited to hear the #FDA approved #IMBRUVICA. Should bode very well for $ABBV. And I think it's 8% price hike of #Humira is reasonable (though I realize those taking the drug may disagree).